$Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.$

Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.

BACKGROUND: We investigated the association of different subfractions of prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2), such as total PSA (tPSA), complexed PSA (cPSA), free PSA (fPSA), "single-chain Intact fPSA" (fPSA-I), "multi-chain nicked fPSA" (fPSA-...

Full description

Bibliographic Details
Main Authors:	Steuber, T, Niemela, P, Haese, A, Pettersson, K, Erbersdobler, A, Felix Chun, K, Graefen, M, Kattan, M, Huland, H, Lilja, H
Format:	Journal article
Language:	English
Published:	2005

Similar Items

Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
by: Haese, A, et al.
Published: (2003)

Total and gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies
by: Haese, A, et al.
Published: (2003)

Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen.
by: Steuber, T, et al.
Published: (2002)

The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer.
by: Haese, A, et al.
Published: (2003)

Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
by: Haese, A, et al.
Published: (2001)

Discrimination of prostate cancer from benign disease by selective measurements of serum subfractions of free PSA that are not internally cleaved at Lys145-Lys146
by: Nurmikko, P, et al.
Published: (2002)

Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer.
by: Haese, A, et al.
Published: (2000)

Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
by: Haese, A, et al.
Published: (2005)

Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
by: Steuber, T, et al.
Published: (2006)

Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer.
by: Steuber, T, et al.
Published: (2007)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer
by: Becker, C, et al.
Published: (2003)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
by: Becker, C, et al.
Published: (2003)

Simultaneous quantification of prostate-specific antigen and human glandular kallikrein 2 mRNA in blood samples from patients with prostate cancer and benign disease.
by: Ylikoski, A, et al.
Published: (2002)

Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.
by: Cao, Y, et al.
Published: (2002)

Simultaneous quantification of human glandular kallikrein 2 and prostate-specific antigen mRNAs in peripheral blood from prostate cancer patients.
by: Ylikoski, A, et al.
Published: (2001)

Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer.
by: Haese, A, et al.
Published: (2004)

[Isoforms of free prostate-specific antigen]
by: Haese, A, et al.
Published: (2004)

Isoforms of free prostate-specific antigen
by: Haese, A, et al.
Published: (2004)

Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
by: Becker, C, et al.
Published: (2000)

Taxon-specific evolution of glandular kallikrein genes and identification of a progenitor of prostate-specific antigen.
by: Olsson, A, et al.
Published: (2004)

Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater.
by: Becker, C, et al.
Published: (2000)

Standardization of two immunoassays for human glandular kallikrein 2.
by: Haese, A, et al.
Published: (2003)

Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum.
by: Piironen, T, et al.
Published: (2006)

Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments.
by: Väisänen, V, et al.
Published: (2006)

Sensitive and specific immunodetection of human glandular kallikrein 2 in serum.
by: Becker, C, et al.
Published: (2000)

Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues.
by: Olsson, A, et al.
Published: (2005)

Prediction of tumor heterogeneity in localized prostate cancer.
by: Huland, H, et al.
Published: (2002)

The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease.
by: Becker, C, et al.
Published: (2001)

Development of sensitive immunoassays for free and total human glandular kallikrein 2.
by: Väisänen, V, et al.
Published: (2004)

Time-resolved fluorescence imaging for specific and quantitative immunodetection of human kallikrein 2 and prostate-specific antigen in prostatic tissue sections.
by: Siivola, P, et al.
Published: (2000)

Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy.
by: Steuber, T, et al.
Published: (2007)

Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer.
by: Janssen, S, et al.
Published: (2004)

Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.
by: Björk, T, et al.
Published: (2001)

Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy.
by: Wenske, S, et al.
Published: (2009)

Prostate kallikrein markers in diagnosis, risk stratification and prognosis.
by: Ulmert, D, et al.
Published: (2009)

The evolution of the glandular kallikrein locus: identification of orthologs and pseudogenes in the cotton-top tamarin.
by: Olsson, A, et al.
Published: (2004)

Rapid elimination by glomerular filtration of free prostate specific antigen and human kallikrein 2 after renal transplantation.
by: Bruun, L, et al.
Published: (2004)

Bladder drainage and glandular epithelial morphometry of the prostate in benign prostatic hyperplasia with severe symptoms
by: Carlos A. Cury, et al.
Published: (2006-04-01)

Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146.
by: Nurmikko, P, et al.
Published: (2001)

Sensitive and specific enzymatic assay for the determination of precursor forms of prostate-specific antigen after an activation step.
by: Niemelä, P, et al.
Published: (2002)